Stacks & blends

Combinations, with the caveats attached.

People rarely use one compound. Here are the pairings that come up most, the pre-mixed blends sold as single vials, why people use them, and what nobody has tested. None of these is a recommendation.

4 stacks 5 blends Stack workshop

StackTwo or more compounds used in the same period, usually from separate vials on separate schedules. Each one can be adjusted or stopped on its own.
BlendSeveral compounds pre-mixed in one vial at a fixed ratio. One draw delivers all of them at once, so none can be adjusted alone, and the mixture itself has never been tested in a trial.

Common stacks

Separate compounds used together, and the reasoning behind each pairing.

Common stackNo combination data

Wolverine

BPC-157 + TB-500. The internet's favorite repair pairing.

BPC-157CTB-500C

Why people combine these

Both are pitched for soft-tissue repair through different proposed mechanisms, so people assume the effects add up.

BPC-157: proposed angiogenic (VEGFR2, nitric oxide) and fibroblast-migration effects in rodent and cell models.
TB-500: proposed actin-binding, cell-migration and angiogenic effects, extrapolated from full-length thymosin beta-4 research.

Caution

Neither compound has a completed human efficacy trial. The pair has never been studied together.
Both are pro-angiogenic in theory. With any cancer history, that is a reason for a specialist conversation, not a forum thread.
Both are prohibited in sport (WADA S0 and S2.3).
Gray-market purity and dose accuracy multiply: two unverified vials, two sets of unknowns.

What is unknown

?Whether effects add, overlap or cancel in humans.
?Whether local and systemic dosing differ in people.
?Long-term safety of either compound, alone or together.

Common stackNo combination data

CJC-1295 (no DAC) + Ipamorelin

A GHRH analog plus a ghrelin-receptor agonist. Two triggers, one GH pulse.

CJC-1295CIpamorelinC

Why people combine these

GHRH analogs and ghrelin-receptor agonists raise GH through different receptors, and animal data suggest they can act synergistically on the pulse.

CJC-1295 without DAC (mod GRF 1-29): a short-acting GHRH analog that amplifies the pituitary's own pulse.
Ipamorelin: a selective ghrelin-receptor agonist that triggers GH release with little cortisol or prolactin effect in animal data.

Caution

No trial has tested the combination for body composition, recovery or ageing.
Stacking GH triggers stacks GH side effects: water retention, tingling or numbness, and changes in glucose handling.
Growth signaling (GH and IGF-1) is a concern with any cancer history.
Both are prohibited in sport (WADA S2.2.4). An FDA advisory committee voted against adding either to the compounding list in 2024.

What is unknown

?Whether the synergy seen in animals translates to meaningful outcomes in people.
?Effects of years of repeated pulses on glucose, joints or tumor risk.

Caution cardNo combination data

Repair + GH-axis

A caution card: BPC-157 or TB-500 layered on a GH secretagogue.

BPC-157CCJC-1295CIpamorelinC

Why people combine these

The pitch is that GH and IGF-1 support collagen synthesis while repair peptides direct it. It is a reasonable-sounding story built entirely on extrapolation.

GH and IGF-1 do influence collagen and connective tissue in human physiology.
The repair peptides' mechanisms are proposed from animal work only.

Caution

Layers growth signaling on top of proposed pro-angiogenic signaling. That is the combination to be most careful with if there is any cancer history.
Three compounds, three injection schedules, three product-quality questions.
All members are prohibited in sport.

What is unknown

?Everything about the combination in humans. There are no data.

Caution cardNo combination data

GLP + anything

A caution card: adding peptides on top of semaglutide, tirzepatide or retatrutide.

Any GLP drugAnything else

Why people combine these

People add repair or GH-axis peptides hoping to protect lean mass or settle GI side effects during rapid weight loss.

Incretin drugs already change appetite, gastric emptying, glucose and, at higher doses, heart rate.
GH-axis peptides also move glucose handling, in a different direction.

Caution

Adding unverified compounds makes it impossible to tell which one caused a side effect.
GH secretagogues can worsen glucose tolerance while the GLP drug is improving it. Nobody has studied what happens in between.
If the GLP drug is prescribed, the prescriber needs to know about everything else. That is the whole point of a prescription.

What is unknown

?Interaction data for any research peptide with any incretin drug.

Blends

Pre-mixed vials sold under a single name. Compositions shown are the most common formats; the label on any given vial is what counts.

Blend · 2 compounds

CJC/Ipa

The classic GH-axis pair, pre-mixed in one vial.

Also called CJC-1295 (no DAC) + Ipamorelin, Mod GRF 1-29 + Ipamorelin

WADA prohibited

Typical vial · 10 mg total

Commonly sold as 10 mg vials with 5 mg of each. Other splits exist, so the label on the vial decides every calculation.

Why people use it

The two are usually taken together anyway, so a single vial means one reconstitution and one injection instead of two.

What the fixed ratio means

At 1:1 by mass, every draw delivers equal amounts of both. Neither can be raised or lowered on its own.

Caution

Both are prohibited in sport (WADA S2.2.4).
An FDA advisory committee voted against adding either to the compounding list in 2024.
GH-axis side effects stack: water retention, tingling, glucose changes.

What is unknown

?Whether the pair stays stable together once mixed in solution.
?Any outcome data for the combination in people.

Evidence shown is the weakest component (Grade C, thin human data). The blend itself has no published human data. Vial math for blends runs per component; the reconstitution calculator works on one component at a time.

Blend · 2 compounds

Tesa/Ipa

An approved GHRH analog's molecule, blended with a secretagogue.

Also called Tesamorelin + Ipamorelin

WADA prohibited

Typical vial · 8 mg total

Ratios vary widely by seller, for example 6 mg/2 mg or 12 mg/2 mg. A different ratio changes every number that follows.

Why people use it

It borrows tesamorelin's reputation as an approved drug and pairs it with ipamorelin for a second GH trigger.

What the fixed ratio means

At 3:1, each draw carries three parts tesamorelin to one part ipamorelin. Tesamorelin's label doses do not transfer to a blend.

Caution

Research-market tesamorelin is not Egrifta. Only the labeled product has FDA-reviewed quality.
Both components are prohibited in sport (WADA S2.2.4).
Tesamorelin's label warns about worsened glucose tolerance.

What is unknown

?Any trial of tesamorelin combined with ipamorelin.
?Stability of the mixed solution.

Blend · 2 compounds

Wolverine blend

The Wolverine stack, sold as one vial.

Also called BPC-157 + TB-500, BPC/TB

WADA prohibited

Typical vial · 10 mg total

Often 5 mg of each; 10 mg of each is also sold.

Why people use it

Convenience: the most popular repair pairing without two separate vials.

What the fixed ratio means

At 1:1, the daily habit discussed for BPC-157 and the twice-weekly habit discussed for TB-500 collapse into one schedule, which neither compound was ever discussed on.

Caution

Neither component has a completed human efficacy trial.
Both are prohibited in sport (WADA S0 and S2.3).
Both are pro-angiogenic in theory, a concern with any cancer history.

What is unknown

?Everything about the combination in people.
?Stability of the mixed solution.

Blend · 3 compounds

GLOW

A skin and repair blend built around copper peptide.

Also called GHK-Cu + BPC-157 + TB-500, Glow stack

WADA prohibited

Typical vial · 70 mg total

Most often 70 mg total (50/10/10). 50 mg versions with other ratios are also sold.

Why people use it

Marketed for skin, hair and recovery: copper peptide for remodeling, plus the two popular repair peptides.

What the fixed ratio means

GHK-Cu is about 71% of the vial by mass. Every draw that delivers 1 mg of GHK-Cu also delivers 200 mcg each of BPC-157 and TB-500.

Caution

Injectable GHK-Cu has no published human trials; its better evidence is topical and cosmetic.
BPC-157 and TB-500 are prohibited in sport.
Three unverified compounds in one vial means three quality questions in one purchase.

What is unknown

?Any human data on the blend.
?Whether copper-bound GHK interacts with the other peptides in solution.

Blend · 4 compounds

KLOW

GLOW with the anti-inflammatory tripeptide KPV added.

Also called GHK-Cu + BPC-157 + TB-500 + KPV, GLOW + KPV

WADA prohibited

Typical vial · 80 mg total

Most often 80 mg total (50/10/10/10).

Why people use it

KPV is added for its proposed anti-inflammatory signaling, pitched at gut and skin inflammation.

What the fixed ratio means

GHK-Cu is about 62% of the vial by mass. Every 1 mg of GHK-Cu comes with 200 mcg each of BPC-157, TB-500 and KPV.

Caution

KPV has no completed human efficacy trial (Grade D here).
Four compounds means four sets of unknowns, and none can be adjusted or stopped on its own.
Contains WADA-prohibited components.

What is unknown

?Any human data on the blend.
?How four peptides behave together in one solution.

Evidence shown is the weakest component (Grade D, little useful signal). The blend itself has no published human data. Vial math for blends runs per component; the reconstitution calculator works on one component at a time.

Stack workshop

Put up to three on the bench.

The workshop shows cadence conflicts, overlapping side effects, the evidence floor and the unknowns. It does not produce a combined schedule, because no such thing has been studied.

Repair

Metabolic

GH-axis

Longevity

Immune

Cognitive

Skin

Sexual

BPC-157

Daily

TB-500

2×/wk

Empty slot

This is the Wolverine stack. Read the full rationale and cautions.

CadenceConflict

Mixed rhythms: BPC-157 is daily, TB-500 is 2× weekly. There is no shared schedule here, only separate ones running at once.

Overlapping reported side effects

Injection-site reactionsBPC-157 + TB-500
HeadacheBPC-157 + TB-500
Unknown long-term profileBPC-157 + TB-500

The bench is only as evidenced as BPC-157 (Grade C: thin human data), and the combination itself has no data at all.

WADA prohibited: BPC-157, TB-500.

Same category, overlapping claims. Overlap is not synergy.

No published human data on this exact combination. Dosing, interactions and long-term effects are unstudied.

The workshop will never produce a combined calendar. There is no evidence base for one.